Trials / Completed
CompletedNCT02303002
Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 268 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum Toxin Type A | Intramuscular injection (IM) |
| BIOLOGICAL | Active Comparator botulinum toxin | IM injection |
| BIOLOGICAL | Placebo Comparator | IM injection |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-12-01
- Completion
- 2016-01-01
- First posted
- 2014-11-27
- Last updated
- 2016-03-09
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02303002. Inclusion in this directory is not an endorsement.